MedTrace Logo

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

NCT02685969 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 570

Last updated 2025-05-31

No results posted yet for this study

Summary

Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.

Cross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project.

Study without therapeutic interest for the research participants (440 participants of the ALFA project who have been selected for being cognitively healthy and in their vast majority are direct descendants of patients diagnosed with Alzheimer's Disease).

Each study candidate will be selected from the ALFA project (STUDY 45-65 FPM/2012) according to their clinical characteristics, their compliance to selection criteria and their desire to participate in this study.

After signing this study's specific informed consent form, the neuropsychological screening and the brain MRI acquisition will be performed. Once all inclusion criteria are checked, the PET scans with 18F-Flutemetamol and 18F-FDG will be performed

Conditions

Interventions

PROCEDURE

18F-Flutemetamol & 18F-FDG

Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • General Electric

    collaborator INDUSTRY

  • Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

    lead OTHER

Principal Investigators

  • Jose Luis Molinuevo, MD, PhD · Scientific Director

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02685969 on ClinicalTrials.gov